rs1801394 — MTRR A66G
B12 recycling enzyme — regenerates active B12 for the methylation cycle
Details
- Gene
- MTRR
- Chromosome
- 5
- Risk allele
- G
- Protein change
- p.Ile22Met
- Consequence
- Missense
- Inheritance
- Codominant
- Clinical
- Benign
- Evidence
- Moderate
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
Methylation & DetoxMTRR — The B12 Recycling Enzyme
Methionine synthase reductase (MTRR) is a critical support enzyme in the methylation cycle. Its job is to reactivate methionine synthase (MTR) after it becomes oxidized and inactive during normal operation. Think of MTRR as the maintenance crew that keeps the methylation assembly line running.
The Mechanism
MTR uses methylcobalamin 11 Methylcobalamin: the methyl-carrying form of vitamin B12, one of two bioactive cobalamin forms (active B12) as a cofactor to convert homocysteine to methionine. During this reaction, B12 occasionally becomes oxidized to an inactive form. MTRR steps in to reduce (reactivate) the B12, restoring MTR function. The A66G variant (rs1801394) causes an isoleucine-to-methionine substitution 22 Isoleucine-to-methionine substitution at position 22 of the protein (p.Ile22Met) at position 22, which reduces MTRR's ability to perform this reactivation efficiently. ClinVar classifies this as benign given its very high population frequency, though functional studies show reduced enzyme affinity for MTR.
The Evidence
The GG genotype has been associated with elevated homocysteine33 associated with elevated homocysteine
Gueant-Rodriguez RM et al. MTRR and neural tube defect risk, 2003 levels in
several studies, though the effect is typically smaller than that of MTHFR
C677T. A meta-analysis44 meta-analysis
Botto LD & Yang Q. Meta-analysis of one-carbon metabolism variants and NTD risk, 2006 found that the G allele modestly increases the risk
of neural tube defects and is associated with altered DNA methylation patterns.
The variant is extremely common — about 50% of Europeans are heterozygous (AG)
and 25% are homozygous (GG).
B12 Form Matters
Because MTRR affects B12 reactivation, the form of B12 you consume may matter. Hydroxocobalamin is the preferred form because it can be readily converted to both methylcobalamin (for methylation) and adenosylcobalamin 55 Adenosylcobalamin is the mitochondrial form of B12, essential for energy metabolism via the citric acid cycle (for energy metabolism). Cyanocobalamin (the cheapest supplement form) requires additional conversion steps and may be less efficient if your MTRR is compromised.
Practical Implications
If you carry the G allele, ensuring adequate B12 intake becomes more important than average. This is especially relevant for vegetarians and vegans who may already be at risk for B12 deficiency. Active B12 forms (hydroxocobalamin, methylcobalamin, adenosylcobalamin) may be preferable to cyanocobalamin.
Interactions
MTRR works in concert with MTR (rs1805087) — both variants affect B12 handling in the methylation cycle. Combined with MTHFR variants (rs1801133), impairment at multiple points compounds the effect on overall methylation capacity.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal B12 recycling
Your MTRR enzyme efficiently recycles oxidized B12 back to its active form, keeping your B12-dependent methylation running smoothly. About 25% of Europeans share this genotype.
Mildly reduced B12 recycling
You carry one variant allele, which somewhat reduces B12 recycling efficiency. Combined with other methylation variants, this may increase your B12 needs. About 50% of people share this genotype.
Reduced B12 recycling — may need more B12
You have two copies of this variant. Your B12 recycling is less efficient, which may increase your B12 requirements. About 25% of Europeans share this genotype.
Key References
MTRR A66G variant associated with elevated homocysteine and neural tube defect risk
Meta-analysis of one-carbon metabolism gene variants and neural tube defect risk
Meta-analysis of MTRR A66G polymorphism and leukemia risk
Population study of folate cycle gene variants and homocysteine levels